IgA Anticardiolipin in Patients with Gastroenteric Tumor

Recently the presence of antiphospholipid antibodies in patients with cancer has been demonstrated, suggesting an involvement of autoimmune response in neoplastic conditions. The presence of antiphospholipid antibodies in tumor disease is highly correlated with the risk of developing thrombotic complications, which represents a significant cause of morbidity and mortality in cancer patients. Interestingly, it has been highlighted that high levels of IgM and IgG anticardiolipin antibodies are more often produced in patients with gastroenteric tumor than in patients with either ovarian or breast tumor. Thus far, there are no data looking into the role or measurements of IgA in patients with solid cancer. Our preliminary results, in this study, demonstrate that testing only for IgG and IgM anticardiolipin antibodies may increase the incidence of false positive because 44% who were IgA positive and IgG and IgM negative had high titres of CA19.9 and CEA. We suggest that taking into account the role of IgA could substantially improve the detection of antiphospholipids antibodies in subjects with solid cancer, and this detection may allow us for better prevention and management of thrombotic complications in these patients.

[1]  A. Macpherson,et al.  The functional interactions of commensal bacteria with intestinal secretory IgA , 2007, Current opinion in gastroenterology.

[2]  K. McCoy,et al.  APRIL in the intestine: a good destination for immunoglobulin A(2). , 2007, Immunity.

[3]  G. M. Iverson,et al.  Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. , 2006, Journal of autoimmunity.

[4]  Y. Shoenfeld,et al.  The catastrophic antiphospholipid (Asherson's) syndrome and malignancies. , 2006, Autoimmunity reviews.

[5]  G. M. Iverson,et al.  IgA antibodies to beta2-glycoprotein I and atherosclerosis. , 2006, Autoimmunity reviews.

[6]  M. Viola-Magni,et al.  Antiphospholipid Antibodies in Patients with Cancer , 2006, International journal of immunopathology and pharmacology.

[7]  C. Gordon,et al.  Clinical significance of IgA anticardiolipin and anti-β2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome , 2006, Clinical Rheumatology.

[8]  H. Nagura,et al.  Immunoglobulin A Enteropathy: A Possible Variant of Henoch–Schönlein Purpura , 2004, Digestive Diseases and Sciences.

[9]  R. Schneider,et al.  Childhood acute myelomonocytic leukemia (AML-M4) presenting as catastrophic antiphospholipid antibody syndrome. , 2004, Journal of pediatric hematology/oncology.

[10]  A. Svennerholm,et al.  Relationship Between Interdigestive Motility and Secretion of Immunoglobulin A in Human Proximal Small Intestine , 1997, Digestive Diseases and Sciences.

[11]  T. Barbui,et al.  Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. , 2004, The hematology journal : the official journal of the European Haematology Association.

[12]  G. Hughes,et al.  Value of IgA anticardiolipin and anti-β2-glycoprotein I antibody testing in patients with pregnancy morbidity , 2003, Annals of the rheumatic diseases.

[13]  T. Shakespeare,et al.  High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis , 2003, Lupus.

[14]  W. Gersony,et al.  Elevated IgA and IgM Anticardiolipin Antibodies in Acute Kawasaki Disease , 2002, Cardiology.

[15]  B. Chiang,et al.  Increased transforming growth factor‐beta (TGF‐β)‐secreting T cells and IgA anti‐cardiolipin antibody levels during acute stage of childhood Henoch–Schönlein purpura , 2000, Clinical and experimental immunology.

[16]  L. Espinoza,et al.  IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. , 1999, The American journal of the medical sciences.

[17]  Y. Mizushima,et al.  Clinical significance of immunoglobulin A antiphospholipid antibodies: possible association with skin manifestations and small vessel vasculitis. , 1998, The Journal of rheumatology.

[18]  Piette Jc,et al.  Towards improved criteria for the antiphospholipid syndrome , 1998, Lupus.

[19]  J. Piette,et al.  Towards improved criteria for the antiphospholipid syndrome. , 1998, Lupus.

[20]  M. Vilardell‐Tarrés,et al.  IgA Anticardiolipin Antibodies – Relation with other Antiphospholipid Antibodies and Clinical Significance , 1998, Thrombosis and Haemostasis.

[21]  A. Gharavi,et al.  Significance of IgA antiphospholipid antibodies , 1998, Lupus.

[22]  T. Barbui,et al.  Antiphospholipid Antibodies: Predictive Value of Laboratory Tests , 1997, Thrombosis and Haemostasis.

[23]  M. Petri.  Pathogenesis and treatment of the antiphospholipid antibody syndrome. , 1997, The Medical clinics of North America.

[24]  E. Holme,et al.  IgA class anticardiolipin antibodies in cutaneous leukocytoclastic vasculitis. , 1996, Journal of the American Academy of Dermatology.

[25]  J. Barker,et al.  Induction of Thrombosis in a Mouse Model by IgG, IgM and IgA Immunoglobulins from Patients with the Antiphospholipid Syndrome , 1995, Thrombosis and Haemostasis.

[26]  D. Tillman,et al.  IgA anticardiolipin antibodies associated with Henoch-Schönlein purpura. , 1994, Journal of the American Academy of Dermatology.

[27]  J. Mekalanos,et al.  Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium , 1992, Infection and immunity.

[28]  A. Verheyen,et al.  Maternal and fetal complications associating lupus anticoagulant and its management; three case reports. , 1990, European journal of obstetrics, gynecology, and reproductive biology.

[29]  O. Vaarala,et al.  Anticardiolipin response in acute infections. , 1986, Clinical immunology and immunopathology.